Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xcid is a brand name primarily used in the Indian pharmaceutical market for a range of gastrointestinal and anti-inflammatory medications. The brand encompasses several distinct formulations, most commonly gastrointestinal treatments: **Xcid Syrup**, a combination of magaldrate (an antacid) and simethicone (an anti-flatulent) used to relieve acidity and bloating; **Xcid D** and **Xcid DSR**, which combine the proton pump inhibitor (PPI) rabeprazole with the prokinetic agent domperidone for the management of gastroesophageal reflux disease (GERD) and peptic ulcers; and **Xcid L**, which pairs rabeprazole with levosulpiride. Additionally, the brand name is used for meloxicam, a non-steroidal anti-inflammatory drug (NSAID) used for pain and inflammation in conditions like arthritis. These medications work through multiple mechanisms, including the neutralization of gastric acid, inhibition of the H+/K+ ATPase pump to reduce acid secretion, antagonism of dopamine D2 receptors to enhance gastric motility, and inhibition of cyclooxygenase enzymes to reduce prostaglandin synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xcid.